BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30981008)

  • 21. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.
    Dolinšek J; Rižnik P; Sabath L; Mičetić-Turk D
    Wien Klin Wochenschr; 2016 Apr; 128(7-8):253-9. PubMed ID: 26659704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.
    Baillet P; Cadiot G; Goutte M; Goutorbe F; Brixi H; Hoeffel C; Allimant C; Reymond M; Obritin-Guilhen H; Magnin B; Bommelaer G; Pereira B; Hordonneau C; Buisson A
    World J Gastroenterol; 2018 Feb; 24(5):641-650. PubMed ID: 29434453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease.
    Grover Z; Burgess C; Muir R; Reilly C; Lewindon PJ
    J Crohns Colitis; 2016 Oct; 10(10):1159-64. PubMed ID: 26980840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
    Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.
    Eder P; Stawczyk-Eder K; Łykowska-Szuber L; Krela-Kaźmierczak I; Klimczak K; Szymczak A; Szachta P; Linke K
    Pol Arch Med Wewn; 2014; 124(1-2):51-7. PubMed ID: 24424551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study.
    Giugliano FP; Strisciuglio C; Martinelli M; Andreozzi M; Cenni S; Campione S; D'Armiento M; Staiano A; Miele E
    Dig Liver Dis; 2018 Mar; 50(3):240-246. PubMed ID: 29174208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Ricciuto A; Fish J; Carman N; Walters TD; Church PC; Hansen BE; Crowley E; Siddiqui I; Nguyen GC; Kamath BM; Griffiths AM
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1098-1105.e1. PubMed ID: 29378308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.
    Eder P; Stawczyk-Eder K; Korybalska K; Czepulis N; Luczak J; Lykowska-Szuber L; Krela-Kazmierczak I; Linke K; Witowski J
    World J Gastroenterol; 2017 Jan; 23(1):135-140. PubMed ID: 28104989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The new simplified MARIA score applies beyond clinical trials: A suitable clinical practice tool for Crohn's disease that parallels a simple endoscopic index and fecal calprotectin.
    Roseira J; Ventosa AR; de Sousa HT; Brito J
    United European Gastroenterol J; 2020 Dec; 8(10):1208-1216. PubMed ID: 32664824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal Markers of Inflammation and Disease Activity in Pediatric Crohn Disease: Results from the ImageKids Study.
    Leach ST; Day AS; Messenger R; Walters TD; Navas-López VM; Sladek M; Brückner A; Yerushalmi B; Saeed S; Otley A; Mack D; Gavish M; Turner D; Griffiths AM; Lemberg DA;
    J Pediatr Gastroenterol Nutr; 2020 May; 70(5):580-585. PubMed ID: 31899733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study.
    Kim ES; Lee HS; Kim SK; Kim EY; Jang BI; Kim KO; Yang CH; Lee YJ;
    Scand J Gastroenterol; 2020 Feb; 55(2):163-168. PubMed ID: 31984815
    [No Abstract]   [Full Text] [Related]  

  • 39. Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn's disease evaluated by double-balloon endoscopy.
    Han W; Wu J; Zhang P; Hu N; Mei Q; Hu J
    Int J Colorectal Dis; 2022 Sep; 37(9):1953-1961. PubMed ID: 35927341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
    Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.